Bronstein, Gewirtz & Grossman Files Class Action Against ARS Pharmaceuticals

Bronstein, Gewirtz & Grossman, LLC, a prominent investor-rights law firm, has filed a class action lawsuit against ARS Pharmaceuticals Inc., a Nasdaq-listed company trading under the ticker symbol SPRY. The lawsuit, which alleges that ARS and certain of its officers violated federal securities laws, was brought on behalf of investors who purchased or acquired ARS securities between March 9, 2026, and June 24, 2026.

According to the complaint, ARS and its officers made materially false and misleading statements to investors, while simultaneously concealing material adverse information regarding the expected timeline for expanded insurance coverage for their neffy product through CVS Caremark. The firm’s press release encourages investors who purchased ARS securities during the class period to visit its website at bgandg.com/cases/ars-pharmaceuticals-inc-spry-class_action_lawsuit to obtain more information and potentially join the lawsuit.

Bronstein, Gewirtz & Grossman, LLC, urges all ARS investors who believe they may have suffered losses due to these alleged misrepresentations to act quickly. The firm states that investors have until October 5, 2026, to request that the court appoint them as lead plaintiff. Participation in the case is not required to share in any potential recovery, and the firm will handle all associated costs and expenses, including legal fees.

The lawsuit highlights a significant period of alleged mismanagement and misleading information dissemination by ARS Pharmaceuticals Inc. The firm’s actions are aimed at restoring investor capital and ensuring corporate accountability, which is central to maintaining market integrity.

Investors who are interested in learning more about the case or seeking legal advice are encouraged to visit the firm's website or contact Peretz Bronstein, Esq., or Nathan Miller, Client Relations Manager, of Bronstein, Gewirtz & Grossman, LLC, at 917-590-0911.